secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vor Biopharma Inc. (VOR)
CIK:        0001817229
Form:       8-K
Filed at:   2025-07-22T23:59:59+00:00
Accession:  0001193125-25-162644
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vor Bio appoints Qing Zuraw as CDO, Michel Detheux and Bo Cumbo as directors
----------------------------------------------------------------------------

- Resignation of director Sven (Bill) Ante Lundberg effective July 17, 2025; no disagreement cited.
- Qing Zuraw appointed CDO; over 25 years in autoimmune diseases; previously led telitacicept trials at RemeGen.
- Zuraw's compensation: $565k base salary, 40% target bonus, $200k signing bonus, 4.37M options, 937k RSUs.
- Board expanded to 10; Michel Detheux (CEO iTeos) and Alexander Cumbo (CEO Solid Biosciences) as independent directors.
- New directors receive $40k cash retainer, initial 60k options, annual 30k options per standard policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525162644/0001193125-25-162644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817229/000119312525162644/d24616d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-162644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer